Literature DB >> 18355268

Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis.

A Iorio1, E Oliovecchio, M Morfini, P M Mannucci.   

Abstract

National haemophilia registries are powerful instruments to support health care and research. A national registry was established in Italy by the Ministry of Health until 1999. Since 2003 the Italian Association of Haemophilia Centres (AICE) started a new programme aiming at building up the Italian Registry of Haemophilia and Allied Disorders. The AICE identified an expert panel to steer the registry. A computer software to assist patient management was developed and all the AICE-affiliated haemophilia treatment centres (HTC) were prompted to adopt it. Twice a year a predefined set of anonymized data is centralized and merged into a national database. Duplicated entries are managed through a confidentiality sparing mechanism. The database covers sociodemographic, clinical, laboratory and treatment data. A subset of data are shared with the Ministry of Health (Istituto Superiore di Sanità,ISS).Overall, data were collected six times by 43 of 49 HTC; 41 centres updated their patients' records up to December 2006. The database contains 6632 unique records, 442 of them referring to dead patients. Database growth and missing data clearance showed a constantly positive trend over time. The database has collected records of the following alive patients - haemophilia A: 1364 severe, 398 moderate and 935 mild; haemophilia B: 231 severe, 138 moderate and 204 mild; von Willebrand's disease: 1208 type 1, 346 type 2 and 96 type 3. Inhibitor patients were 296 (of which 194 high responders and 65 low responders).The Italian registry run by AICE adds to the list of the available national haemophilia registries and is intended to establish treatment guidelines and foster research projects in Italy.

Entities:  

Mesh:

Year:  2008        PMID: 18355268     DOI: 10.1111/j.1365-2516.2008.01679.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  17 in total

1.  Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.

Authors:  Alessandra Rocca; Simona Pizzinelli; Emily Oliovecchio; Elena Santagostino; Angiola Rocino; Alfonso Iorio
Journal:  Blood Transfus       Date:  2010-04-30       Impact factor: 3.443

2.  Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International Registry.

Authors:  David C Dale; Audrey Anna Bolyard; Laurie A Steele; Cornelia Zeidler; Karl Welte
Journal:  Curr Opin Hematol       Date:  2020-01       Impact factor: 3.284

Review 3.  Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates.

Authors:  Antonio Coppola; Annarita Tagliaferri; Gabriele Calizzani; Fabio Candura; Massimo Franchini; Carlo Ruosi; Giuliano Grazzini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

4.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

Review 5.  Uncovered needs in the management of inherited bleeding disorders in Italy.

Authors:  Romano Arcieri; Angelo C Molinari; Stefania Farace; Giuseppe Mazza; Alberto Garnero; Gabriele Calizzani; Paola Giordano; Emily Oliovecchio; Lorenzo Mantovani; Lamberto Manzoli; Paul Giangrande
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

6.  Current status of Italian Registries on inherited bleeding disorders.

Authors:  Hamisa Jane Hassan; Massimo Morfini; Domenica Taruscio; Francesca Abbonizio; Adele Giampaolo; Yllka Kodra; Emily Oliovecchio; Luciano Vittozzi
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

7.  Difficulties in the treatment of an Infant with Hemophilia B.

Authors:  Serdar Özkasap; Selim Dereci; Gül Nihal Özdemir; Bülent Zülfikar
Journal:  Turk Pediatri Ars       Date:  2016-06-01

Review 8.  Alloantibodies in von Willebrand disease.

Authors:  Paula D James; David Lillicrap; Pier M Mannucci
Journal:  Blood       Date:  2013-01-07       Impact factor: 22.113

9.  Definition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders.

Authors:  Gabriele Calizzani; Ivana Menichini; Fabio Candura; Monica Lanzoni; Samantha Profili; Maria Rita Tamburrini; Antonio Fortino; Stefania Vaglio; Giuseppe Marano; Giuseppina Facco; Emily Oliovecchio; Massimo Franchini; Antonio Coppola; Romano Arcieri; Cinzia Bon; Mario Saia; Sabina Nuti; Massimo Morfini; Giancarlo M Liumbruno; Giovanni Di Minno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

10.  The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients.

Authors:  Patricia Pinto; Tejashree Shelar; Vidhya Nawadkar; Darshana Mirgal; Alfiya Mukaddam; Preethi Nair; Priyanka Kasatkar; Tejasvita Gaikwad; Shahnaz Ali; Anshul Jadli; Rucha Patil; Anita Parihar; Sharda Shanbhag; Bipin Kulkarni; Kanjaksha Ghosh; Shrimati Shetty
Journal:  Indian J Hematol Blood Transfus       Date:  2014-02-05       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.